Abstract:Background and Purpose: Myocardial infarction (MI) in diabetic patients results in higher mortality and morbidity. We and others have previously shown that bone marrow-endothelial progenitor cells (EPCs) promote cardiac neovascularization and attenuate ischemic injury. Lately, small extracellular vesicles (EVs) have emerged as major paracrine effectors mediating the benefits of stem cell therapy. Modest clinical outcomes of autologous cell-based therapies suggest diabetes-induced EPC dysfunction and may also reflect their EV derivatives. Moreover, studies suggest that post-translational histone modifications promote diabetes-induced vascular dysfunctions. Therefore, we tested the hypothesis that diabetic EPC-EVs may lose their post-injury cardiac reparative function by modulating histone modification in endothelial cells (ECs). Methods: We collected EVs from the culture medium of EPCs isolated from non-diabetic (db/+) and diabetic (db/db) mice and examined their effects on recipient ECs and cardiomyocytes in vitro, and their reparative function in permanent ligation of left anterior descending (LAD) coronary artery and ischemia/reperfusion (I/R) myocardial ischemic injuries in vivo. Results: Compared to db/+ EPC-EVs, db/db EPC-EVs promoted EC and cardiomyocyte apoptosis and repressed tube-forming capacity of ECs. In vivo, db/db EPC-EVs depressed cardiac function, reduced capillary density, and increased fibrosis compared to db/+ EPC-EV treatments after MI. Moreover, in the I/R MI model, db/+ EPC-EV-mediated acute cardio-protection was lost with db/db EPC-EVs, and db/db EPC-EVs increased immune cell infiltration, infarct area, and plasma cardiac troponin-I. Mechanistically, histone 3 lysine 9 acetylation (H3K9Ac) was significantly decreased in cardiac ECs treated with db/db EPC-EVs compared to db/+ EPC-EVs. The H3K9Ac chromatin immunoprecipitation sequencing (ChIP-Seq) results further revealed that db/db EPC-EVs reduced H3K9Ac level on angiogenic, cell survival, and proliferative genes in cardiac ECs. We found that the histone deacetylase (HDAC) inhibitor, valproic acid (VPA), partly restored diabetic EPC-EV-impaired H3K9Ac levels, tube formation and viability of ECs, and enhanced cell survival and proliferative genes, Pdgfd and Sox12, expression. Moreover, we observed that VPA treatment improved db/db EPC-mediated post-MI cardiac repair and functions. Conclusions: Our findings unravel that diabetes impairs EPC-EV reparative function in the ischemic heart, at least partially, through HDACs-mediated H3K9Ac downregulation leading to transcriptional suppression of angiogenic, proliferative and cell survival genes in recipient cardiac ECs. Thus, HDAC inhibitors may potentially be used to restore the function of diabetic EPC and other stem cells for autologous cell therapy applications.

Helix B Surface Peptide Attenuates Diabetic Cardiomyopathy Via Ampk-Dependent Autophagy

Helix B surface peptide attenuates injury of mouse diabetic cardiomyopathy and possible mechanism

Helix B surface peptide is cardioprotective through inhibition on myocardial apoptosis induced by ischemia/reperfusion injury

Helix B surface peptide administered after insult of ischemia reperfusion improved renal function, structure and apoptosis through beta common receptor/erythropoietin receptor and PI3K/Akt pathway in a murine model.

Autophagy and Akt in the protective effect of erythropoietin helix B surface peptide against hepatic ischaemia/reperfusion injury in mice

Dihydromyricetin Prevents Diabetic Cardiomyopathy via miR-34a Suppression by Activating Autophagy

Highly Selective Hydrogenation of Furfural to Furan-2-ylmethanol over a Cu/C Derived from Copper-Organic Frameworks

A Novel Oral Glucagon-Like Peptide 1 Receptor Agonist Protects Against Diabetic Cardiomyopathy Via Alleviating Cardiac Lipotoxicity Induced Mitochondria Dysfunction

Hsp20-Mediated Activation of Exosome Biogenesis in Cardiomyocytes Improves Cardiac Function and Angiogenesis in Diabetic Mice

S-Propargyl-Cysteine Attenuates Diabetic Cardiomyopathy in db/db Mice Through Activation of Cardiac Insulin Receptor Signaling

DIABETIC CARDIOMYOPATHY ATTENUATING ERYTHROPOIETIN-INDUCED CARDIOPROTECTION AGAINST ISCHAEMIC-REPERFUSION INJURY VIA RISK PATHWAY

Glucagon-Like Peptide 1 Protects against Hyperglycemic-Induced Endothelial-to-Mesenchymal Transition and Improves Myocardial Dysfunction by Suppressing Poly(ADP-Ribose) Polymerase 1 Activity

Berberine Ameliorates Diabetic Cardiomyopathy in Mice by Decreasing Cardiomyocyte Apoptosis and Oxidative Stress

Diabetes impairs cardioprotective function of endothelial progenitor cell-derived extracellular vesicles via H3K9Ac inhibition

Abstract 14965: Pharmacological Targeting of the Hexosamine Biosynthesis Pathway (HBP) Overcomes Diabetes-Induced Impaired Myocardial Inotropic Responsiveness to Α1-Adrenoceptor (Α1-Ar) Stimulation

Inhibition of Advanced Glycation Endproduct (AGE) Rescues Against Streptozotocin-Induced Diabetic Cardiomyopathy: Role of Autophagy and ER Stress.

Cardiac-Specific Overexpression of HIF-1α Prevents Deterioration of Glycolytic Pathway and Cardiac Remodeling in Streptozotocin-Induced Diabetic Mice

Astragalus Polysaccharides Protect Cardiac Stem and Progenitor Cells by the Inhibition of Oxidative Stress-Mediated Apoptosis in Diabetic Hearts

Icariin Ameliorates Diabetic Cardiomyopathy Through Apelin/Sirt3 Signalling to Improve Mitochondrial Dysfunction

Adiponectin Ameliorates Hyperglycemia-Induced Cardiac Hypertrophy and Dysfunction by Concomitantly Activating Nrf2 and Brg1

Ginsenoside Rg1 Ameliorates Diabetic Cardiomyopathy by Inhibiting Endoplasmic Reticulum Stress‐induced Apoptosis in a Streptozotocin‐induced Diabetes Rat Model